Company Overview and News

5
Is First Trust STOXX European Select Dividend Index Fund (FDD) a Hot ETF Right Now?

2h zacks
The First Trust STOXX European Select Dividend Index Fund (FDD - Free Report) made its debut on 08/27/2007, and is a smart beta exchange traded fund that provides broad exposure to the European Equity ETFs category of the market.
RDS.B RDS.A RYDBF GSK IQDE RDSB IQDF RDSA RYDAF GSK

1
This Knight Is Ready To Battle Back

3h seekingalpha
Blueknight Energy Partners is an undercovered name that has a been a disaster for its investors.
RDS.B RDS.A RYDBF RDSB RDSA RYDAF

12
The ‘Lower for Longer’ Oil Mantra Fades as Prices Top $80

18h theedgemarkets
(Sept 25): The commitment to live with “lower for longer” oil might not last that long after all.
XOM BP RDSB RDSA GS GLSSP RYDAF FP JBK RDS.B RDS.A GSC TFG BP.A BP.B GSJ BP CVX RYDBF BPAQF GJS

2
Shell Exec Says Canada Pipeline Debacle Won't Affect LNG Decision

18h rigzone
(Bloomberg) -- The debacle over Canada's oil pipeline nationalization and trade tensions with the U.S. won't affect the final investment decision on Royal Dutch Shell Plc's C$40 billion ($31 billion) liquefied natural gas project, according to the head of the venture.
RDS.B RDS.A KMI RYDBF RDSB RDSA RYDAF KMR CVB KMRFZ

12
Lower for Longer's Days May Be Numbered

22h rigzone
(Bloomberg) -- The commitment to live with "lower for longer" oil might not last that long after all.
XOM BP RDSB RDSA GS GLSSP RYDAF FP JBK RDS.B RDS.A GSC TFG BP.A BP.B GSJ BP CVX RYDBF BPAQF GJS

4
Big Oil pledges to slash potent greenhouse gas emission

2018-09-24 theedgemarkets
LONDON (Sept 24): A group of the world's top oil and gas companies pledged on Monday to slash emissions of a potent greenhouse gas by a fifth by 2025 in an effort to battle climate change.
RDS.B RDS.A XOM RYDBF RDSB RDSA RYDAF

6
Shell (RDS.A) to Sell Stakes in GoM's Caesar Tonga Field?

2018-09-24 zacks
Reportedly, Royal Dutch Shell plc (RDS.A - Free Report) is in talks to offload its stakes in the Gulf of Mexico (GoM) oilfield, moving ahead with its divestment goals. The company is planning to vend its 22.5% interest in Caesar Tonga field to Focus Oil for approximately $1.3 billion. Notably, Caesar Tonga field is jointly held by Anadarko Petroleum corporation (APC - Free Report) , Shell, Equinor ASA (EQNR - Free Report) and Chevron Corporation (CVX - Free Report) , with Shell owning 22.
APC KBH BRGYY RDS.B RDS.A RDSB RDSA BG BRGXF CVX RYDBF RYDAF AEUA

4
Big Oil pledges to slash potent greenhouse gas emission

2018-09-24 reuters
LONDON (Reuters) - A group of the world’s top oil and gas companies pledged on Monday to slash emissions of a potent greenhouse gas by a fifth by 2025 in an effort to battle climate change.
RDS.B RDS.A XOM RYDBF RDSB RDSA RYDAF

1
Gazprom: Political Risk Lifts Over Nordstream 2

2018-09-24 seekingalpha
To say that the Nordstream 2 pipeline is controversial is the height of understatement. This pipeline, now officially under construction by Gazprom (OTCPK:OGZPY), lies at the center of a number of hot-button geopolitical imperatives.
RDS.B RDS.A RYDBF RDSB RDSA RYDAF

1
RPT-INSIGHT-In Nigeria, Shell’s onshore roots still run deep

2018-09-24 reuters
BODO, Nigeria, Sept 23 (Reuters) - Royal Dutch Shell wants to reweight its footprint in Nigeria to focus on oil and gas fields far offshore, away from the theft, spills, corruption and unrest that have plagued the West African country’s onshore industry for decades.
RDS.B RDS.A RYDBF RDSB RDSA RYDAF

4
RPT-TIMELINE-Shell's operations in Nigeria

2018-09-24 reuters
LONDON, Sept 23 (Reuters) - Royal Dutch Shell pioneered Nigeria’s oil and gas industry and remains a major investor in the West African country. But over the decades it has come under fire over spills in the Delta region and struggles with oil theft, corruption and oil-fueled violence.
BP RDS.B RDS.A RYDBF BP RDSB BPAQF RDSA RYDAF BP.A BP.B

4
Timeline: Shell's operations in Nigeria

2018-09-23 reuters
LONDON (Reuters) - Royal Dutch Shell pioneered Nigeria’s oil and gas industry and remains a major investor in the West African country. But over the decades it has come under fire over spills in the Delta region and struggles with oil theft, corruption and oil-fueled violence.
BP RDS.B RDS.A RYDBF BP RDSB BPAQF RDSA RYDAF BP.A BP.B

1
In Nigeria, Shell’s onshore roots still run deep

2018-09-23 reuters
BODO, Nigeria (Reuters) - Royal Dutch Shell wants to reweight its footprint in Nigeria to focus on oil and gas fields far offshore, away from the theft, spills, corruption and unrest that have plagued the West African country’s onshore industry for decades.
RDS.B RDS.A RYDBF RDSB RDSA RYDAF

1
In Nigeria, Shell’s onshore roots still run deep

2018-09-23 channelnewsasia
Royal Dutch Shell wants to reweight its footprint in Nigeria to focus on oil and gas fields far offshore, away from the theft, spills, corruption and unrest that have plagued the West African country's onshore industry for decades.
RDS.B RDS.A RYDBF RDSB RDSA RYDAF

1
INSIGHT-In Nigeria, Shell’s onshore roots still run deep

2018-09-23 reuters
BODO, Nigeria, Sept 23 (Reuters) - Royal Dutch Shell wants to reweight its footprint in Nigeria to focus on oil and gas fields far offshore, away from the theft, spills, corruption and unrest that have plagued the West African country’s onshore industry for decades.
RDS.B RDS.A RYDBF RDSB RDSA RYDAF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...